- Home
- VRNT vs AUPH Comparison
VRNT vs AUPH Comparison
Compare VRNT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNT
- AUPH
- Stock Information
- Founded
- VRNT 1994
- AUPH 1993
- Country
- VRNT United States
- AUPH Canada
- Employees
- VRNT N/A
- AUPH N/A
- Industry
- VRNT EDP Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- VRNT Technology
- AUPH Health Care
- Exchange
- VRNT Nasdaq
- AUPH Nasdaq
- Market Cap
- VRNT 1.1B
- AUPH 1.1B
- IPO Year
- VRNT N/A
- AUPH 1999
- Fundamental
- Price
- VRNT $21.50
- AUPH $7.58
- Analyst Decision
- VRNT Buy
- AUPH Strong Buy
- Analyst Count
- VRNT 6
- AUPH 2
- Target Price
- VRNT $30.33
- AUPH $11.50
- AVG Volume (30 Days)
- VRNT 2.7M
- AUPH 1.6M
- Earning Date
- VRNT 09-03-2025
- AUPH 07-31-2025
- Dividend Yield
- VRNT N/A
- AUPH N/A
- EPS Growth
- VRNT 79.53
- AUPH N/A
- EPS
- VRNT 0.84
- AUPH 0.27
- Revenue
- VRNT $896,006,000.00
- AUPH $247,295,000.00
- Revenue This Year
- VRNT $7.65
- AUPH $12.15
- Revenue Next Year
- VRNT $5.54
- AUPH $18.31
- P/E Ratio
- VRNT $25.50
- AUPH $28.53
- Revenue Growth
- VRNT N/A
- AUPH 29.20
- 52 Week Low
- VRNT $14.15
- AUPH $5.20
- 52 Week High
- VRNT $37.31
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- VRNT 66.61
- AUPH 40.36
- Support Level
- VRNT $18.50
- AUPH $7.29
- Resistance Level
- VRNT $22.84
- AUPH $8.86
- Average True Range (ATR)
- VRNT 1.33
- AUPH 0.34
- MACD
- VRNT 0.40
- AUPH -0.06
- Stochastic Oscillator
- VRNT 79.88
- AUPH 19.37
About VRNT Verint Systems Inc.
Verint Systems Inc with its subsidiaries, helps brands provide Boundless customer experience (CX) automation. AI offers a solution, and that's where Verint comes in. It empowers brands with groundbreaking AI via a next-gen open platform. Its Verint Open Platform helps organizations increase CX automation to achieve their strategic objectives and realize ROI. Geographically, it derives a majority of its revenue from the United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.